title: Role of Homocysteine in the Ischemic Stroke and Development of Ischemic Tolerance.
abstract: Homocysteine (Hcy) is a toxic, sulfur-containing intermediate of methionine metabolism. Hyperhomocysteinemia (hHcy), as a consequence of impaired Hcy metabolism or defects in crucial co-factors that participate in its recycling, is assumed as an independent human stroke risk factor. Neural cells are sensitive to prolonged hHcy treatment, because Hcy cannot be metabolized either by the transsulfuration pathway or by the folate/vitamin B12 independent remethylation pathway. Its detrimental effect after ischemia-induced damage includes accumulation of reactive oxygen species (ROS) and posttranslational modifications of proteins via homocysteinylation and thiolation. Ischemic preconditioning (IPC) is an adaptive response of the CNS to sub-lethal ischemia, which elevates tissues tolerance to subsequent ischemia. The main focus of this review is on the recent data on homocysteine metabolism and mechanisms of its neurotoxicity. In this context, the review documents an increased oxidative stress and functional modification of enzymes involved in redox balance in experimentally induced hyperhomocysteinemia. It also gives an interpretation whether hyperhomocysteinemia alone or in combination with IPC affects the ischemia-induced neurodegenerative changes as well as intracellular signaling. Studies document that hHcy alone significantly increased Fluoro-Jade C- and TUNEL-positive cell neurodegeneration in the rat hippocampus as well as in the cortex. IPC, even if combined with hHcy, could still preserve the neuronal tissue from the lethal ischemic effects. This review also describes the changes in the mitogen-activated protein kinase (MAPK) protein pathways following ischemic injury and IPC. These studies provide evidence for the interplay and tight integration between ERK and p38 MAPK signaling mechanisms in response to the hHcy and also in association of hHcy with ischemia/IPC challenge in the rat brain. Further investigations of the protective factors leading to ischemic tolerance and recognition of the co-morbid risk factors would result in development of new avenues for exploration of novel therapeutics against ischemia and stroke.
authors.affiliation: Institute of Medical Biochemistry and BioMed, Jessenius Faculty of Medicine, Comenius University in Bratislava Martin, Slovakia.
authors.forename: Ján
authors.initials: J
authors.lastname: Lehotský
authors.affiliation: Institute of Medical Biochemistry and BioMed, Jessenius Faculty of Medicine, Comenius University in Bratislava Martin, Slovakia.
authors.forename: Barbara
authors.initials: B
authors.lastname: Tothová
authors.affiliation: Institute of Medical Biochemistry and BioMed, Jessenius Faculty of Medicine, Comenius University in BratislavaMartin, Slovakia; Institute of Histology and Embryology, Jessenius Faculty of Medicine, Comenius University in BratislavaMartin, Slovakia.
authors.forename: Maria
authors.initials: M
authors.lastname: Kovalská
authors.affiliation: Institute of Medical Biochemistry and BioMed, Jessenius Faculty of Medicine, Comenius University in Bratislava Martin, Slovakia.
authors.forename: Dušan
authors.initials: D
authors.lastname: Dobrota
authors.affiliation: Institute of Medical Biochemistry and BioMed, Jessenius Faculty of Medicine, Comenius University in Bratislava Martin, Slovakia.
authors.forename: Anna
authors.initials: A
authors.lastname: Beňová
authors.affiliation: Institute of Medical Biochemistry and BioMed, Jessenius Faculty of Medicine, Comenius University in Bratislava Martin, Slovakia.
authors.forename: Dagmar
authors.initials: D
authors.lastname: Kalenská
authors.affiliation: Institute of Medical Biochemistry and BioMed, Jessenius Faculty of Medicine, Comenius University in Bratislava Martin, Slovakia.
authors.forename: Peter
authors.initials: P
authors.lastname: Kaplán
keywords: MAP kinases; brain; hyperhomocysteinemia; intracellular signaling; ischemic preconditioning; neurodegeneration